Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial

Author:

Tannu Manasi12ORCID,Kaltenbach Lisa3,Pagidipati Neha J.12ORCID,McGuire Darren K.4ORCID,Aroda Vanita R.5ORCID,Pop-Busui Rodica6ORCID,Kondamudi Nitin7,Al-Khalidi Hussein R.13ORCID,Lopes Renato D.12ORCID,Cavender Matthew A.8,Nelson Adam J.1ORCID,Kirk Julienne9,Lingvay Ildiko4ORCID,Magwire Melissa10,Richardson Caroline Regina6ORCID,Webb Laura2ORCID,Leyva Monica2,Pandey Ambarish4ORCID,Washington Alana11,Pak Jonathan12,Gaynor Tanya12,Khan Waqar13,Weston Patrick11,Granger Christopher B.12,Green Jennifer12ORCID

Affiliation:

1. Duke Clinical Research Institute, Durham, NC (M.T., N.J.P., H.R.A.-K., R.D.L., A.J.N., C.B.G., J.G.).

2. Duke University School of Medicine, Durham, NC (M.T., N.J.P., R.D.L., L.W., M.L., C.B.G., J.G.).

3. Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC (L.K., H.R.A.-K.).

4. University of Texas Southwestern Medical Center and Parkland Health, Dallas (D.K.M., I.L., A.P.).

5. Brigham and Women’s Hospital, Boston, MA (V.R.A.).

6. University of Michigan, Ann Arbor (R.P.-B., C.R.R.).

7. Department of Cardiology, University of Washington Medical Center, Seattle (N.K.).

8. Department of Cardiology, University of North Carolina, Chapel Hill (M.A.C.).

9. Wake Forest University, Winston-Salem, NC (J.K.).

10. Saint Luke’s Health System–Haverty Cardiometabolic Center of Excellence/Cardiometabolic Center Alliance, Kansas City, MO (M.M.).

11. Northwestern University, Evanston, IL (P.W.).

12. Boehringer Ingelheim Pharmaceuticals, Inc, Ingelheim, Germany (J.P., T.G.).

13. Lonestar Heart and Vascular Center, North Houston, Tomball, TX (W.K.).

Abstract

BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based medical therapies to participants with type 2 diabetes and atherosclerotic cardiovascular disease. This secondary analysis assessed whether intervention success was consistent across sex, race, and ethnicity. METHODS: COORDINATE-Diabetes, a cluster randomized trial, recruited participants from 43 US cardiology clinics (20 randomized to intervention and 23 randomized to usual care). The primary outcome was the proportion of participants prescribed all 3 groups of evidence-based therapy (high-intensity statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide 1 receptor agonist) at last trial assessment (6 to 12 months). In this prespecified analysis, mixed-effects logistic regression models were used to assess the outcome by self-reported sex, race, and ethnicity in the intervention and usual care groups, with adjustment for baseline characteristics, medications, comorbidities, and site location. RESULTS: Among 1045 participants with type 2 diabetes and atherosclerotic cardiovascular disease, the median age was 70 years, 32% were female, 16% were Black, and 9% were Hispanic. At the last trial assessment, there was an absolute increase in the proportion of participants prescribed all 3 groups of evidence-based therapy in women (36% versus 15%), Black participants (41% versus 18%), and Hispanic participants (46% versus 18%) with the intervention compared with usual care, with consistent benefit across sex (male versus female; P interaction =0.44), race (Black versus White; P interaction =0.59), and ethnicity (Hispanic versus Non-Hispanic; P interaction = 0.78). CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials. REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03936660.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3